Madrigal Pharma Updates Business Address in 8-K Filing
Ticker: MDGL · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1157601
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance
TL;DR
**Madrigal Pharma just updated its official business address, a minor administrative change.**
AI Summary
Madrigal Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to update its business address to Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania 19428. This change, while seemingly minor, is important for investors as it ensures official communications and regulatory filings are directed to the correct location, reflecting operational stability and proper corporate governance for MDGL stock.
Why It Matters
This filing indicates a routine administrative update to Madrigal Pharmaceuticals' corporate address, which is important for official communications and regulatory compliance.
Risk Assessment
Risk Level: low — The filing only reports a change in business address, which is a standard administrative update and does not indicate any operational or financial risks.
Analyst Insight
A smart investor would note this administrative update as routine and not indicative of any material operational or financial changes for Madrigal Pharmaceuticals, Inc. (MDGL).
Key Players & Entities
- MADRIGAL PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of earliest event reported
- Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania 19428 (address) — new principal executive office address
- MDGL (company) — trading symbol for Madrigal Pharmaceuticals, Inc.
- The NASDAQ Stock Market LLC (company) — exchange where MDGL Common Stock is registered
FAQ
What is the primary purpose of this 8-K filing by Madrigal Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing, dated January 8, 2024, is to report a change in Madrigal Pharmaceuticals, Inc.'s principal executive office address to Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania 19428.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 8, 2024.
What is the trading symbol and the exchange where Madrigal Pharmaceuticals, Inc.'s common stock is registered?
Madrigal Pharmaceuticals, Inc.'s common stock trades under the symbol MDGL and is registered on The NASDAQ Stock Market LLC.
What was Madrigal Pharmaceuticals, Inc.'s previous business address, if mentioned?
The filing indicates the previous address was '200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428' in the filer information, and the new address is 'Four Tower Bridge 200 Barr Harbor Drive, Suite 200 West Conshohocken, Pennsylvania 19428'.
Does this 8-K filing indicate any changes in the company's financial status or operations?
No, this 8-K filing, under Item 5.02 'Other Events', solely reports an administrative change to the company's business address and does not provide any information regarding changes in financial status or operations.
Filing Stats: 451 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-01-08 13:45:01
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MDGL The NASDAQ
Filing Documents
- d669791d8k.htm (8-K) — 25KB
- d669791dex991.htm (EX-99.1) — 19KB
- g669791ex99_1s10g1.jpg (GRAPHIC) — 115KB
- g669791ex99_1s11g1.jpg (GRAPHIC) — 92KB
- g669791ex99_1s1g1.jpg (GRAPHIC) — 115KB
- g669791ex99_1s2g1.jpg (GRAPHIC) — 215KB
- g669791ex99_1s3g1.jpg (GRAPHIC) — 85KB
- g669791ex99_1s4g1.jpg (GRAPHIC) — 105KB
- g669791ex99_1s5g1.jpg (GRAPHIC) — 70KB
- g669791ex99_1s6g1.jpg (GRAPHIC) — 111KB
- g669791ex99_1s7g1.jpg (GRAPHIC) — 92KB
- g669791ex99_1s8g1.jpg (GRAPHIC) — 86KB
- g669791ex99_1s9g1.jpg (GRAPHIC) — 92KB
- 0001193125-24-004269.txt ( ) — 1798KB
- mdgl-20240108.xsd (EX-101.SCH) — 3KB
- mdgl-20240108_lab.xml (EX-101.LAB) — 18KB
- mdgl-20240108_pre.xml (EX-101.PRE) — 11KB
- d669791d8k_htm.xml (XML) — 3KB
01
Item 8.01. Other Events On January 8, 2024, Madrigal Pharmaceuticals, Inc. (the "Company") posted to its website a corporate presentation slide deck that the Company intends to use for investor communications. A copy of the corporate presentation slide deck is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) The following exhibits are filed as part of this report: Exhibit Number Description 99.1 Corporate Presentation of Madrigal Pharmaceuticals, Inc. (January 8, 2024) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Madrigal Pharmaceuticals, Inc. (the Registrant) Date: January 8, 2024 By: /s/ Brian J. Lynch Brian J. Lynch Senior Vice President and General Counsel